The Prostate Test Doctors Stopped Recommending Is Back — What Changed

For sixteen years, the official advice to American men about prostate cancer screening was, in essence: decide for yourself. The American Cancer Society's guidance since 2010 told men to weigh the advantages and disadvantages with their doctor, and stopped short of recommending routine testing at all. On Thursday, November 12, the organisation reversed that position. In new guidance published in CA: A Cancer Journal for Clinicians, it now recommends regular PSA blood testing for most men — every two years for average-risk men aged 50 to 69, and every year from age 45 for Black men and men with a strong family history. It is the first time the society has endorsed routine prostate screening, and it changes the conversation millions of men will have with their doctors. This article is general information only and is not medical advice.

What the new guideline actually says

The core of the new guidance is a simple, risk-stratified schedule. Average-risk men should have a PSA test — a blood test measuring prostate-specific antigen — every two years from age 50 through age 69. Men at higher risk should start earlier and test more often: Black men, and non-Black men with a strong family history of prostate cancer, should be screened annually from age 45 through 69. The emphasis on earlier screening for Black men reflects a stark disparity: according to the American Cancer Society, Black men have a 67% higher incidence of prostate cancer and nearly double the mortality rate of white men.

The guideline also lowers the threshold for acting on a result. A confirmed PSA level of 3.0 nanograms per millilitre or higher in men aged 45 to 69 — or 6.5 or higher in men aged 70 to 74 — should trigger a repeat blood test within two weeks to three months, followed by an MRI scan or biomarker testing before any biopsy is scheduled. That last step is deliberate: the MRI-first approach is designed to cut down on unnecessary biopsies, one of the harms that made screening controversial in the first place. The society also reaffirmed that it does not recommend the digital rectal exam as a primary screening tool.

For older men, the advice stays cautious. The balance of benefits and harms remains uncertain for men aged 70 to 74, who should discuss screening with their doctors. Routine screening is not recommended for men aged 75 and older, although very healthy men aged 75 to 79 with a rising PSA may want to continue — and it is not recommended for men aged 80 and older, or for men not expected to live another ten years. And when a biopsy does find a slow-growing, low-risk cancer, the guideline says active surveillance — monitoring the cancer rather than treating it immediately — should be the preferred first approach.

Why the reversal: the evidence changed

The society says the change reflects stronger long-term evidence that routine screening reduces prostate cancer deaths, combined with modern diagnostic tools that reduce the harms. The centrepiece is the European Randomized Study of Screening for Prostate Cancer, which followed more than 160,000 men across eight countries for up to 23 years and found roughly a 20% relative reduction in prostate cancer mortality among men invited to screening. A 2026 systematic review and meta-analysis of five randomised trials covering 721,607 men pointed the same way.

The harms have not disappeared — they have been managed better. The old objection to screening was never that PSA testing fails to find cancers; it was that it finds too many harmless ones, leading to biopsies, surgery and side effects for men who would never have been harmed by their cancer. The new pathway — repeat testing, then MRI, then biopsy only if the imaging supports it, then active surveillance for low-risk disease — is designed to keep the benefit while cutting the overtreatment. As the society's chief scientific officer, Dr. William Dahut, put it in the announcement, the possible benefits now outweigh the potential harms given medical advances and accumulating evidence.

The scale of the disease explains why the decision matters. The American Cancer Society estimates that 333,830 American men will be diagnosed with prostate cancer in 2026, and 36,320 will die of it. It remains one of the most common cancers in men — and one where catching the lethal cases early, while leaving the harmless ones alone, is the whole game.

The new 3.0 threshold — and why your lab report may lag

One detail in the new guideline could cause confusion in the short term: the threshold for follow-up has dropped from 4.0 to 3.0 nanograms per millilitre. The old 4.0 benchmark came from a 1986 study of just 472 healthy men, and it has been the number most American laboratories print on their reports ever since. Under the new guidance, a PSA of 3.0 or above in a man under 70 should now prompt further evaluation — which means a result your lab still flags as "normal" may, under the new standard, deserve a second look. Laboratories will take time to update their reference ranges, so men should ask their doctor which threshold is being applied, rather than reading the flag on the report alone.

There is also a coverage wrinkle. The US Preventive Services Task Force, whose recommendations determine whether insurers must cover screening without cost-sharing, still sits on its 2018 guidance — a cautious recommendation for men aged 55 to 69 and a recommendation against screening for men 70 and older. Its update is listed as in progress, with no release date announced, and legislation that would close the gap remains in committee. The cancer society's own advocacy arm wrote to the health department in May urging the task force to move faster. Until that happens, a man who follows the new guidance may find his insurer does not yet pay for it.

The practical takeaway is narrower than the headlines suggest. The new guideline does not say every man should rush for a test tomorrow. It says men aged 50 to 69 should be offered one every two years, men at higher risk should start at 45, and everyone should still receive information about the risks and benefits before testing begins. What has changed is the default: for sixteen years, the default was "your choice, we won't recommend it". From now on, the default is "yes — unless there is a reason not to". For a disease that kills more than 36,000 American men a year, that is a consequential shift in a single sentence.